Jakarta, October 21, 2025 – PT Etana Biotechnologies Indonesia (Etana) reinforce its commitment to delivering high-quality, innovative, and halalcompliant ealth products. This commitment is realized through obtaining the halal certificate for its Enoxaparin Sodium product from the Assessment Institute for Foods, Drugs, and Cosmetics of the Indonesian Ulema Council (LPPOM MUI).
Read MoreJakarta, 30 September 2025 - PT Etana Biotechnologies Indonesia (Etana) has officially signed a strategic partnership with DEG Impulse, a subsidiary of DEG - Deutsche Investitions- und Entwicklungsgesellschaft mbH, to implement a digital transformation of the company’s core quality management system.
Read MoreJakarta, August 28, 2025 – PT Etana Biotechnologies Indonesia (Etana) has officially been designated as one of the Centers of Excellence for Vaccine and Biotechnology Development by the Ministry of Health of the Republic of Indonesia. The designation is stated in the Decree of the Director General of Pharmaceuticals and Medical Devices No. HK.02.02/E/1504/2025.
Read MoreJakarta, July 14, 2025 – PT Etana Biotechnologies Indonesia (Etana), a national biopharmaceutical company focused on developing treatments for metabolic and chronic diseases, has signed a collaboration agreement with Universitas Indonesia Hospital (RSUI) to conduct clinical research on therapy for Type 2 Diabetes Mellitus.
Read MoreJakarta, June 12, 2025 – Etana Biotechnologies Indonesia (Etana) has officially entered into a partnership with the Faculty of Military Pharmacy of University of Defense (Unhan) to strengthen collaboration in education, research, and community service.
Read MoreJakarta, May 19, 2025 – PT Etana Biotechnologies Indonesia (Etana) confirmed its dedication to helping Indonesia become self-sufficient in pharmaceuticals by getting approval for Clinical Trials (PPUK) and a Marketing Authorization Number (NIE) from the Indonesian Food and Drug Authority (BPOM RI) for two important products.
Read More
